CAJ | 학술논문

目的探讨利妥昔单抗联合化疗及造血干细胞移植治疗难治性弥漫大B细胞淋巴瘤(DL-BCL)的临床疗效和安全性评价.方法回顾性分析1例应用利妥昔单抗联合化疗及造血干细胞移植治疗的难治性DLBCL患者的临床资料,并结合文献复习对此方法治疗难治性DLBCL的临床疗效和安全性进行评价.结果 1例难治性DLBCL患者先后予各种方案化疗后未获得缓解,改为利妥昔单抗联合化疗及造血干细胞移植治疗后,造血重建顺利,取得完全缓解,相关并发症控制较好,随访至2010年11月1日一直长期无病生存.结论利妥昔单抗联合化疗及造血干细胞移植治疗难治性DLBCL是安全有效的治疗手段.
목적 탐토리타석단항연합화료급조혈간세포이식치료난치성미만대B세포림파류(DL-BCL)적림상료효화안전성평개.방법 회고성분석1례응용리타석단항연합화료급조혈간세포이식치료적난치성DLBCL환자적림상자료,병결합문헌복습대차방법치료난치성DLBCL적림상료효화안전성진행평개.결과 1례난치성DLBCL환자선후여각충방안화료후미획득완해,개위리타석단항연합화료급조혈간세포이식치료후,조혈중건순리,취득완전완해,상관병발증공제교호,수방지2010년11월1일일직장기무병생존.결론 리타석단항연합화료급조혈간세포이식치료난치성DLBCL시안전유효적치료수단.
Objective To report the clinical efficacy and safety of rimximab combined with autologous hematopoietic stem cell transplantation in a case of refractory diffuse large B cell lymphoma.Methods Clinical data of a case in rituximab combined chemotherapy and hematopoietic stem eell transplantation for refractory difluse large B cell lymphonm was analyzed.The efficacy and safety for the program with literature review were evaluated.Results The patient did not achieve remission with various chemotherapy regimens.After using autologous hematopoietic stem cell translplantation with rituximab,the hematopoietic was rebuilded successfuly,symptoms were complete reIieved,complications wero well controlled.Follow-up to November 1,2010,tIle patient was discasc-free survival.Conclusion Rituximab combined with autologous hematopoietie stem cell transplantation is a safe and effective treatment of refractory diffuse large B cell lymphoma.